ATE288758T1 - Verfahren zur herstellung von polymorphen des clarithromycins - Google Patents

Verfahren zur herstellung von polymorphen des clarithromycins

Info

Publication number
ATE288758T1
ATE288758T1 AT00986367T AT00986367T ATE288758T1 AT E288758 T1 ATE288758 T1 AT E288758T1 AT 00986367 T AT00986367 T AT 00986367T AT 00986367 T AT00986367 T AT 00986367T AT E288758 T1 ATE288758 T1 AT E288758T1
Authority
AT
Austria
Prior art keywords
clarithromycin
polymorphoes
producing
converting
processes
Prior art date
Application number
AT00986367T
Other languages
English (en)
Inventor
Igor Lifshitz
Ilya Avrutov
Edi Schwartz
Basem Masarwa
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22640371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE288758(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE288758T1 publication Critical patent/ATE288758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00986367T 2000-01-11 2000-12-15 Verfahren zur herstellung von polymorphen des clarithromycins ATE288758T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
PCT/US2000/033844 WO2001051059A1 (en) 2000-01-11 2000-12-15 Processes for preparing clarithromycin polymorphs

Publications (1)

Publication Number Publication Date
ATE288758T1 true ATE288758T1 (de) 2005-02-15

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986367T ATE288758T1 (de) 2000-01-11 2000-12-15 Verfahren zur herstellung von polymorphen des clarithromycins

Country Status (22)

Country Link
US (2) US6624292B2 (de)
EP (1) EP1280535B1 (de)
JP (1) JP2003519661A (de)
KR (1) KR20020071012A (de)
CN (1) CN1450903A (de)
AT (1) ATE288758T1 (de)
AU (2) AU2001222619C1 (de)
BR (1) BR0016992A (de)
CA (1) CA2397092A1 (de)
DE (1) DE60018119T2 (de)
DK (1) DK1280535T3 (de)
ES (1) ES2236023T3 (de)
HR (1) HRP20020572A2 (de)
HU (1) HUP0204252A3 (de)
IL (1) IL150698A0 (de)
IS (1) IS6463A (de)
PL (1) PL356645A1 (de)
PT (1) PT1280535E (de)
RU (1) RU2002118308A (de)
SI (1) SI1280535T1 (de)
WO (1) WO2001051059A1 (de)
ZA (1) ZA200205229B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020522A2 (en) * 1999-12-16 2004-12-31 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph iv
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására
ATE432691T1 (de) * 2000-03-28 2009-06-15 Sandoz Ag Geschmackmaskierte granulierte teilchen
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
SI1285659T1 (sl) * 2001-08-13 2008-02-29 Fond Salvatore Maugeri Clinica Uporaba klaritromicinskih sestavkov za pripravo zdravila za zdravljenje deformirajocega artritisa
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
WO2005009364A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
EP1653924A4 (de) 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
EP1701705A4 (de) * 2003-12-24 2007-08-08 Advancis Pharmaceutical Corp Verbesserte absorption von dosierformen mit modifizierter freisetzung
AU2005209318B2 (en) * 2004-01-28 2010-02-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2011026234A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
SG10202012791TA (en) 2013-11-15 2021-01-28 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
ES2173057T3 (es) * 1996-07-29 2004-11-16 Abbott Laboratories Preparacion de la forma ii cristalina de claritromicina.
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
HRP20020522A2 (en) * 1999-12-16 2004-12-31 Teva Pharma Processes for preparing clarithromycin polymorphs and novel polymorph iv
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
HUP0302466A2 (hu) * 2000-02-29 2003-11-28 Teva Pharmaceutical Industries Ltd. Eljárások clarithromycin, clarithromycin intermedier, gyakorlatilag oximmentes clarithromycin és ezt tartalmazó gyógyszerkészítmény előállítására

Also Published As

Publication number Publication date
IL150698A0 (en) 2003-02-12
KR20020071012A (ko) 2002-09-11
ZA200205229B (en) 2003-06-30
AU2261901A (en) 2001-07-24
HRP20020572A2 (en) 2005-04-30
ES2236023T3 (es) 2005-07-16
JP2003519661A (ja) 2003-06-24
AU2001222619C1 (en) 2006-01-12
AU2001222619B8 (en) 2005-07-14
AU2001222619B2 (en) 2005-04-28
EP1280535B1 (de) 2005-02-09
BR0016992A (pt) 2002-12-31
IS6463A (is) 2002-07-09
DE60018119T2 (de) 2006-05-04
PL356645A1 (en) 2004-06-28
US6987175B2 (en) 2006-01-17
RU2002118308A (ru) 2004-02-20
EP1280535A4 (de) 2003-02-05
US6624292B2 (en) 2003-09-23
DE60018119D1 (de) 2005-03-17
EP1280535A1 (de) 2003-02-05
DK1280535T3 (da) 2005-04-04
SI1280535T1 (de) 2005-08-31
HUP0204252A3 (en) 2003-04-28
WO2001051059A1 (en) 2001-07-19
CA2397092A1 (en) 2001-07-19
HUP0204252A2 (hu) 2003-03-28
PT1280535E (pt) 2005-04-29
US20020028920A1 (en) 2002-03-07
US20030216555A1 (en) 2003-11-20
CN1450903A (zh) 2003-10-22

Similar Documents

Publication Publication Date Title
ATE288758T1 (de) Verfahren zur herstellung von polymorphen des clarithromycins
DE60134590D1 (de) Verfahren zur Herstellung von kohlensäurehaltigem Wasser
ATE222899T1 (de) Verfahren zur herstellung von reinem citalopram
DE60130372D1 (de) Tauchformen, zusammensetzung für das tauchformen und verfahren zur herstellung von tauchformen
ATE417107T1 (de) Verfahren zur herstellung von l-aminosäuren durch enterobacteriaceae-stämmen mit verstärkter expression des pts-g
ATE302786T1 (de) Verfahren zur herstllung von clarithromycin polymorphen und polymorph iv
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
ATE281448T1 (de) Verfahren zur herstellung von citalopram
DE50102118D1 (de) Verfahren zur herstelling von 1,2-dichlorethan
ATE328885T1 (de) Verfahren zur herstellung von sulfonamid- substituierten imidazotriazinonen
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
ATE516267T1 (de) Vefahren zur herstellung von lactamen
ATE266004T1 (de) Verfahren zur herstellung von 3-amino-2-chlor-4- methylpyridin
ATE389645T1 (de) Verfahren zur herstellung von citalopram
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
DE50107372D1 (de) Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
ATE374757T1 (de) Verfahren zur herstellung von (1,4,5)- oxadiazepinderivaten
DE60105991D1 (de) Verfahren zur herstellung von 6-aminocapronamid
DE50112449D1 (de) Verfahren zur herstellung von 3,3-diarylpropylaminen
ATE291569T1 (de) Verfahren zur herstellung von dnda
DE50103009D1 (de) Verfahren zur herstellung von 2-alkyl-3-chlorphenolen
ATE425143T1 (de) Verfahren zur herstellung von indolen
DE50002865D1 (de) Verfahren zur herstellung von benzofuranonoximen
ATE387434T1 (de) Verfahren zur herstellung von mintlacton
ATE386015T1 (de) Verfahren zur herstellung von alkyl-n-(3- dimethylamino)alkylcarbamaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280535

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
RZN Patent revoked